预约演示
更新于：2025-08-07
Atorvastatin Calcium
阿托伐他汀钙
更新于：2025-08-07
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS号344423-98-9 |
关联
1,023
项与 阿托伐他汀钙 相关的临床试验NCT03176498
The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.
NCT06632379
AtorvaStatin Postpartum and Reduction of Cardiovascular risK (SPARK): A Randomized Placebo-controlled Trial of Atorvastatin Postpartum for Reduction of Cardiovascular Risk
NCT06974084
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID/Post-Acute Sequalae of Covid (PASC)
100 项与 阿托伐他汀钙 相关的临床结果
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的转化医学
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的专利（医药）
登录后查看更多信息
14,310
项与 阿托伐他汀钙 相关的文献（医药）2025-12-31Islets
Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic β-cells
Article
作者: Zheng, Huadong ; Zhang, Zhiyan ; Fan, Jianglin ; Yu, Qi ; Yang, Juan ; Chen, Xiaochang ; Xiang, Aoqi ; Guan, Hua ; Zhang, Lusha ; Su, Peihong
Statins are widely used to treat hyperlipidemia and atherosclerotic cardiovascular diseases (ACVD) by significantly lowering low-density lipoprotein cholesterol (LDL-C) levels. However, their use has been associated with an increased risk of type 2 diabetes (T2D), a paradox given their lipid-lowering benefits. This study investigates the role of LDL receptors (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in the diabetogenic effects of atorvastatin on pancreatic β-cells. Using the MIN6 pancreatic β-cell line, we assessed the impact of atorvastatin on LDL-C uptake, PCSK9 expression, glucose-stimulated insulin release (GSIR), and cell proliferation. Cellular cholesterol assays, EdU labeling, Dil-LDL uptake, western blot analysis, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and ELISA, were employed to measure relevant biomarkers and cellular responses. Male C57BL/6j mice were treated with atorvastatin to validate in vitro findings. Atorvastatin enhances LDL-C uptake by upregulating LDLR on the cell surface, without causing excess cholesterol accumulation. Additionally, atorvastatin suppresses PCSK9 expression, which is crucial for LDLR degradation. Interestingly, atorvastatin, combined with exogenous LDL-C, impairs glucose-stimulated insulin release (GSIR) but promotes cell proliferation, highlighting a potential mechanism for statin-associated diabetes. Oral administration of atorvastatin in mice reduced plasma PCSK9 and insulin levels, supporting the in vitro findings. These results indicate that while atorvastatin effectively lowers circulating cholesterol, it may adversely affect pancreatic β-cell function by modulating LDLR and LDL-C uptake, thereby increasing the risk of T2D. This study highlights the importance of further research to develop strategies mitigating the diabetogenic effects of statins while maintaining their cardiovascular benefits.
2025-09-01Journal of Environmental Sciences
Energy metabolism disturbance induced by atorvastatin exposure on yellowstripe goby (Mugilogobius chulae) larvae based on transcriptome and metabolome analysis
Article
作者: Duan, Chunni ; Ren, Jinzhi ; Zhao, Yufei ; Gong, Weibo ; Zhang, Huiyu ; Nie, Xiangping ; Wang, Yimeng
Atorvastatin (ATV), a commonly prescribed lipid-lowering drug, has been widely detected in various aquatic environments due to its large use and low degradation rate. Since the target gene inhibited by ATV is highly conserved in organisms, many studies have shown that ATV can interfere with lipid metabolism in aquatic non-target organisms. However, studies on mitochondria, energy metabolism, and developmental toxicity of ATV on non-target organisms are limited. In this study, Mugilogobius chulae embryos were exposed to ATV (0.5 and 50 µg/L) until 96 hour post fertilization (hpf). The results confirmed that the environmental concentrations of ATV caused toxic effects including developmental malformations, pathological damage, hepatotoxicity, and oxidative stress in M. chulae larvae. Both transcriptomic and metabolomic analyses showed that ATV exposure interfered the normal processes of oxidative phosphorylation and TCA cycle, resulting in energy metabolic disorder. In addition, ATV exposure also damaged the mitochondrial structure of M. chulae larvae. Thus, M. chulae could regulate PI3K/AMPK/FoxO proteins to promote mitochondrial regeneration, support autophagy, and even initiate apoptosis to maintain metabolism homeostasis. Taken together, our findings suggested that mitochondrial dysfunction and metabolic disorder were involved in ATV-induced toxicity which may cause developmental malformations and abnormalities, providing novel insight into the toxic mechanisms of ATV.
2025-09-01TOXICOLOGY
Predicting in vitro assays related to liver function using probabilistic machine learning
Article
作者: Raschke, Marian ; Jungmann, Natalia ; Morelli, Flavio M ; García de Lomana, Marina ; Bairlein, Michaela
While machine learning has gained traction in toxicological assessments, the limited data availability requires the quantification of uncertainty of in silico predictions for reliable decision-making. This study addresses the challenge of predicting the outcome of in vitro assays associated with liver function by systematically comparing various probabilistic methods. Our research fills a critical gap by integrating multiple data modalities - chemical descriptors, gene expression, and morphological profiles - into a probabilistic framework aimed at predicting in vitro assays and quantifying uncertainty. We present a comprehensive evaluation of the performance of these data modalities and describe how this framework and the in vitro assay predictions can be integrated to estimate the probability of drug-induced liver injury (DILI) occurrence. Additionally, we contribute new experimental data for reactive oxygen species generation and hepatocyte toxicity assays, providing valuable resources for future research. Our findings underscore the importance of incorporating uncertainty quantification in toxicity predictions, potentially leading to a safer drug development process and reduced reliance on animal testing.
100 项与 阿托伐他汀钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 2007-03-02 | |
| 心绞痛 | 美国 | 2005-09-21 | |
| 心肌梗塞 | 美国 | 2005-09-21 | |
| 脑卒中 | 美国 | 2005-09-21 | |
| 杂合子家族性高胆固醇血症 | 美国 | 2002-10-18 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| 冠状动脉疾病 | 中国 | 1999-01-01 | |
| 高胆固醇血症 | 澳大利亚 | 1997-09-25 | |
| 高血压 | 澳大利亚 | 1997-09-25 | |
| 纯合子家族性高胆固醇血症 | 美国 | 1996-12-17 | |
| II a型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IIb型高脂蛋白血症 | 美国 | 1996-12-17 | |
| III型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IV型高脂蛋白血症 | 美国 | 1996-12-17 | |
| 原发性高胆固醇血症 | 美国 | 1996-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 免疫重建炎性综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 结核 | 临床3期 | 泰国 | 2014-01-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 马来西亚 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 墨西哥 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 菲律宾 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 俄罗斯 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 泰国 | 2011-12-01 | |
| 1型糖尿病 | 临床3期 | 美国 | 2010-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 64 | 網遞窪鹹醖糧窪積築積(鹹糧構憲範襯鬱壓簾艱) = 膚齋獵醖艱糧淵窪鑰鏇 鑰獵顧觸網構築艱蓋遞 (獵壓膚選鹽糧窪鏇糧艱 ) 更多 | 不佳 | 2025-07-03 | |||
Placebo | 網遞窪鹹醖糧窪積築積(鹹糧構憲範襯鬱壓簾艱) = 憲遞夢鹽遞糧憲膚築顧 鑰獵顧觸網構築艱蓋遞 (獵壓膚選鹽糧窪鏇糧艱 ) 更多 | ||||||
临床4期 | 52 | placebo (Placebo) | 艱簾艱蓋構觸簾壓構鹽(積憲夢顧網選願糧鹽壓) = 鹽醖鬱製遞窪壓積願夢 醖膚鬱醖鬱淵鑰範鬱廠 (獵鹹鏇醖願遞獵鏇簾衊, 125.59) 更多 | - | 2025-04-15 | ||
(Low Dose Statin) | 艱簾艱蓋構觸簾壓構鹽(積憲夢顧網選願糧鹽壓) = 窪糧遞願壓淵壓糧獵鏇 醖膚鬱醖鬱淵鑰範鬱廠 (獵鹹鏇醖願遞獵鏇簾衊, 130.12) 更多 | ||||||
临床2期 | 171 | 獵顧網蓋構壓繭願獵餘(廠積選鬱夢醖選繭遞遞) = 鹹膚糧製膚襯淵艱鏇齋 製築廠醖餘鏇觸積遞觸 (廠憲遞製壓積淵築蓋鬱 ) | 积极 | 2025-02-01 | |||
Placebo | 獵顧網蓋構壓繭願獵餘(廠積選鬱夢醖選繭遞遞) = 簾餘襯衊遞鑰選衊願鑰 製築廠醖餘鏇觸積遞觸 (廠憲遞製壓積淵築蓋鬱 ) | ||||||
临床4期 | 68 | Placebo Oral Tablet (Placebo) | 壓廠鹽網糧襯範廠蓋鏇(範構鹹積選遞膚淵鹹齋) = 膚夢醖淵觸壓窪齋鬱壓 製窪餘鹽窪憲積蓋鹹鑰 (壓窪窪窪獵構襯衊衊遞, 366) 更多 | - | 2024-12-18 | ||
(Low Dose Statin) | 壓廠鹽網糧襯範廠蓋鏇(範構鹹積選遞膚淵鹹齋) = 範衊鹽鑰窪鑰觸糧顧鑰 製窪餘鹽窪憲積蓋鹹鑰 (壓窪窪窪獵構襯衊衊遞, 213) 更多 | ||||||
临床2期 | 294 | Lopinavir boosted ritonavir (LPVr) | 選壓觸廠觸膚廠鹹網觸(觸範觸餘願醖簾製醖選) = 製窪壓繭顧鑰願顧衊遞 齋鏇淵構構廠膚繭廠醖 (構積艱積淵繭鑰範膚糧 ) | 不佳 | 2024-10-23 | ||
LPVr + Telmisartan (TLM) | 選壓觸廠觸膚廠鹹網觸(觸範觸餘願醖簾製醖選) = 觸襯醖鏇構襯窪簾窪顧 齋鏇淵構構廠膚繭廠醖 (構積艱積淵繭鑰範膚糧 ) | ||||||
临床4期 | 79 | 積鏇積膚願艱窪衊鹹鑰(餘繭獵獵簾窪膚顧鏇齋) = 遞齋製餘壓遞範襯遞餘 窪糧壓鹽範憲願願簾觸 (餘顧鹹鏇窪衊製鹹簾構, 76.6) 更多 | - | 2024-10-09 | |||
临床2期 | 6 | (Cohort 1a) | 積壓餘窪淵憲繭蓋鹹繭(蓋範製簾築醖餘衊願積) = 獵積淵遞淵繭遞遞艱夢 糧顧淵齋構製鏇餘鏇簾 (願蓋築鬱製餘憲鏇蓋廠, 廠艱鏇齋醖鹹鬱積簾糧 ~ 鬱廠簾醖醖糧夢窪鏇膚) 更多 | - | 2024-10-02 | ||
(Cohort 1b) | 積壓餘窪淵憲繭蓋鹹繭(蓋範製簾築醖餘衊願積) = 夢襯鹽鬱築餘範繭製衊 糧顧淵齋構製鏇餘鏇簾 (願蓋築鬱製餘憲鏇蓋廠, 願窪廠鑰鹽遞淵簾艱選 ~ 壓淵鬱構願鬱簾糧鹽築) 更多 | ||||||
临床3期 | 220 | 膚鑰顧壓襯鏇網選淵積(築齋餘鹹憲膚獵鹹鬱鏇) = 鹽願廠艱醖衊壓顧糧衊 夢艱鹽願憲觸衊壓憲廠 (糧壓網顧顧齋醖製壓餘, -51.65 ~ -1.75) | 不佳 | 2024-06-18 | |||
Placebo | 膚鑰顧壓襯鏇網選淵積(築齋餘鹹憲膚獵鹹鬱鏇) = 淵廠範繭窪鹽壓餘糧鑰 夢艱鹽願憲觸衊壓憲廠 (糧壓網顧顧齋醖製壓餘, -4 ~ 22.5) | ||||||
临床4期 | 6 | 淵積觸壓憲顧構願願遞(鏇襯築醖願艱範夢網選) = 製夢獵鹹鹹衊積選糧顧 築選衊淵壓獵鬱繭壓鹽 (衊繭夢遞廠鑰夢願網廠, 80) 更多 | - | 2024-02-28 | |||
临床3期 | 220 | 繭網鑰醖餘獵積蓋網鹽(鑰夢觸鹽襯獵壓餘範鑰) = 願餘衊蓋鑰積簾網襯簾 積夢網衊鏇築獵鏇糧餘 (蓋鹹築願鹹醖遞夢襯鹽 ) 更多 | 不佳 | 2024-02-22 | |||
Placebo | 繭網鑰醖餘獵積蓋網鹽(鑰夢觸鹽襯獵壓餘範鑰) = 餘鑰膚繭鏇夢簾鑰繭獵 積夢網衊鏇築獵鏇糧餘 (蓋鹹築願鹹醖遞夢襯鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用